S. Himatlal Healthcare LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: S. Himatlal Healthcare LLP Pharmaceutical Export Portfolio Dataset — 5 Products, $106.4K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

S. Himatlal Healthcare LLP — Pharmaceutical Exporter Profile (2026) | 5 Products, $106.4K Trade | TransData Nexus

S. Himatlal Healthcare LLP

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $106.4K Total Trade · DGFT Verified

S. Himatlal Healthcare LLP is an Indian pharmaceutical exporter with a total trade value of $106.4K across 5 products in 3 therapeutic categories. Based on 69 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Vinorelbine ($39.6K), Ifosfamide ($27.2K), Primaquine ($25.3K).

S. Himatlal Healthcare LLP — Export Portfolio & Destination Treemap

S. Himatlal Healthcare LLP pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is S. Himatlal Healthcare LLP? — Company Overview & Market Position

S. Himatlal Healthcare LLP, established on September 14, 2022, is a Mumbai-based pharmaceutical wholesale distributor operating under the Limited Liability Partnership (LLP) structure with CIN/LLPIN: ABC-4253. The company is headquartered at Unit No. B-13, Ground Floor, Mangaldas Building No.1, Mangaldas Market, Princess Street, Kalbadevi, Mumbai, Maharashtra, 400002, India. The authorized capital is ₹0.10 million, with a paid-up capital of ₹0.00. S. Himatlal Healthcare LLP is led by Designated Partners Mukesh Mahendrakumar Doshi and Yogesh Mukeshkumar Doshi, both appointed on September 14, 2022. The company specializes in the wholesale distribution of a diverse range of pharmaceutical products, including branded and generic medicines, super-specialty products, lifesaving drugs, cold chain products, vaccines, and over-the-counter (OTC) items.

What Does S. Himatlal Healthcare LLP Export? — Product Portfolio Analysis

Top Products by Export Value

1Vinorelbine$39.6K 2Ifosfamide

Product Portfolio — Top 5 by Export Value

S. Himatlal Healthcare LLP exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Vinorelbine	Advanced Oncology	$39.6K	8	0.7%	7
2	Ifosfamide	Advanced Oncology	$27.2K	24	1.1%	13
3	Primaquine	Antimalarial & Antiparasitic	$25.3K	10	1.5%	8
4	Soframycin	Brand Names & OTC Products	$11.4K	16	1.9%	3
5	Chlorambucil	Advanced Oncology	$2.9K	11	0.8%	12

S. Himatlal Healthcare LLP exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $106.4K. The top category is Advanced Oncology (65.5% of portfolio), followed by Antimalarial & Antiparasitic (23.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

S. Himatlal Healthcare LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

S. Himatlal Healthcare LLP operates as a pharmaceutical wholesale distributor and does not own or operate manufacturing facilities. The company focuses on sourcing and distributing a wide array of pharmaceutical products, including branded and generic medicines, super-specialty products, lifesaving drugs, cold chain products, vaccines, and over-the-counter (OTC) items.

3Key Leadership

S. Himatlal Healthcare LLP is managed by Designated Partners Mukesh Mahendrakumar Doshi and Yogesh Mukeshkumar Doshi, both appointed on September 14, 2022. The company does not publicly disclose additional details about other key executives or their specific roles.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does S. Himatlal Healthcare LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

S. Himatlal Healthcare LLP's export data indicates shipments to various countries, including Tanzania, Ethiopia, Somalia, Sudan, Mauritania, Madagascar, Chad, Turkey, the Philippines, Pakistan, Nepal, Indonesia, and Russia. However, specific information regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan is not publicly available. The company's focus appears to be on markets in Africa, Asia, and Europe.

2Emerging Markets

S. Himatlal Healthcare LLP has a significant presence in emerging markets, particularly in Africa. The company's export data shows substantial shipments to countries such as Tanzania, Ethiopia, Somalia, Sudan, Mauritania, Madagascar, and Chad. While the company does not explicitly mention WHO prequalification, its extensive distribution in these regions suggests a strategic focus on emerging markets.

3Geographic Strategy

S. Himatlal Healthcare LLP's export data indicates a strong concentration in African markets, with Tanzania accounting for 62.43% of export shipments. This concentration suggests a strategic focus on specific regions, which may expose the company to risks associated with overdependence on particular markets. Diversifying its geographic footprint could mitigate such risks and enhance resilience.

S. Himatlal Healthcare LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As a pharmaceutical wholesale distributor, S. Himatlal Healthcare LLP does not manufacture or market products directly in the United States. Consequently, the company does not have FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history with the FDA.

2WHO & EU GMP

S. Himatlal Healthcare LLP's export data indicates shipments to various countries, including those in Africa and Europe. However, specific information regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available.

3CDSCO & Indian Regulatory

S. Himatlal Healthcare LLP operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers to distribute pharmaceutical products. Specific details regarding export No Objection Certificates (NOCs) are not publicly disclosed.

S. Himatlal Healthcare LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

S. Himatlal Healthcare LLP operates in a competitive pharmaceutical distribution market, with numerous players offering similar products and services. While specific market share data is not publicly available, the company's focus on emerging markets, particularly in Africa, positions it to compete with other distributors targeting these regions.

2Key Differentiators

S. Himatlal Healthcare LLP's extensive product range, including branded and generic medicines, super-specialty products, lifesaving drugs, cold chain products, vaccines, and OTC items, distinguishes it in the market. The company's strategic focus on emerging markets, especially in Africa, demonstrates its commitment to addressing diverse healthcare needs.

3Strategic Position

S. Himatlal Healthcare LLP's current strategic direction emphasizes the wholesale distribution of a broad spectrum of pharmaceutical products, with a notable presence in emerging markets. The company's future outlook may involve expanding its geographic reach and diversifying its product portfolio to enhance market presence and resilience.

Buyer Due Diligence Brief — Evaluating S. Himatlal Healthcare LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

S. Himatlal Healthcare LLP has demonstrated a consistent track record in pharmaceutical distribution, with a total export value of $106,000 USD across 69 shipments. The company's portfolio concentration, with the top five products accounting for 100% of exports, indicates a focused approach. Reliability indicators, such as timely deliveries and adherence to quality standards, are not publicly disclosed but are essential for evaluating the company's performance.

2Certifications to Verify

Importers should verify the following certifications when engaging with S. Himatlal Healthcare LLP:

FDA Registration: Confirm the company's compliance with FDA regulations for pharmaceutical distribution.

WHO-GMP Certification: Ensure that the company's products meet World Health Organization Good Manufacturing Practice standards.

EU GMP Certification: Verify adherence to European Union Good Manufacturing Practice standards.

Frequently Asked Questions — S. Himatlal Healthcare LLP

How many pharmaceutical products does S. Himatlal Healthcare LLP export from India?

S. Himatlal Healthcare LLP exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Vinorelbine ($39.6K), Ifosfamide ($27.2K), Primaquine ($25.3K), Soframycin ($11.4K), Chlorambucil ($2.9K). Total export value is $106.4K.

What is S. Himatlal Healthcare LLP's total pharmaceutical export value?

S. Himatlal Healthcare LLP's total pharmaceutical export value is $106.4K, based on 69 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does S. Himatlal Healthcare LLP cover?

S. Himatlal Healthcare LLP exports across 3 therapeutic categories. The largest are Advanced Oncology (65.5%, 3 products), Antimalarial & Antiparasitic (23.8%, 1 products), Brand Names & OTC Products (10.7%, 1 products).

Get Full S. Himatlal Healthcare LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.